Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study

1999-05-27

Additional Metadata
Keywords	Alendronate, Bisphosphonate, Bone mineral density, Fractures, Postmenopausal osteoporosis
Persistent URL	doi.org/10.1007/PL00004171, hdl.handle.net/1765/74125
Journal	Osteoporosis International: with other metabolic bone diseases
Organisation	Department of Internal Medicine
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Pols, H., Felsenberg, D., Hanley, G., Štepán, J., Muñoz-Torres, M., Wilkin, T., Qin-Sheng, G., Galich, A., Vandormael, M., Yates, A.& Stych, B. (1999). Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Osteoporosis International: With Other Metabolic Bone Diseases, 9(5), 461–468.https://doi.org/10.1007/PL00004171

Publication